Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nano-candesartan
- Development stage
- Preclinical
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Nano-candesartan refers to a nanoparticle-based formulation of the antihypertensive drug candesartan. Candesartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and adrenal glands, resulting in vasodilation and reduced blood pressure. The nanoformulation aims to improve the solubility, bioavailability, and sustained release profile of candesartan compared to conventional oral tablets. Nanoparticle delivery systems for candesartan have been developed using various carriers such as PLGA (poly(lactic-co-glycolic acid)), lipid nanoparticles, or self-nanoemulsifying drug delivery systems (SNEDDS). These formulations are being investigated for enhanced antihypertensive efficacy and potential use in conditions like diabetes-associated stroke due to improved pharmacokinetics and tissue targeting[6][7][8][9].
- Other names
- candesartan nanoparticlecandesartan nanocrystalcandesartan-loaded nanoparticles
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on nano-candesartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nano-candesartan.